07 September 2020: Clinical Research
Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy
Xianghua Zeng 123CDEG* , Shicong Zhu 12BCD* , Cheng Xu 4CF , Zhongyu Wang 12CD , Xingxing Su 12CD , Dong Zeng 12CD , Haixia Long 12AF* , Bo Zhu 12AG*DOI: 10.12659/MSM.922576
Med Sci Monit 2020; 26:e922576
Figure 2 Kaplan-Meier plots of PFS in patients with non-small cell lung cancer undergoing PD1 inhibitors based on comorbidity conditions assessed by Charlson comorbidity index (A) and simplified comorbidity score (B). HR – hazard ratio; CI – confidence interval; PFS – progression-free survival.